Lifecore Historical Income Statement

LFCR Stock

5.84 0.07 1.21%

Historical analysis of Lifecore Biomedical income statement accounts such as Gross Profit of 50.2 M can show how well Lifecore Biomedical performed in making a profits. Evaluating Lifecore Biomedical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Lifecore Biomedical's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Lifecore Biomedical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lifecore Biomedical is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.

About Lifecore Income Statement Analysis

Lifecore Biomedical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Lifecore Biomedical shareholders. The income statement also shows Lifecore investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Lifecore Biomedical Income Statement Chart

At this time, Lifecore Biomedical's Net Income is relatively stable compared to the past year. As of 03/01/2025, Selling General Administrative is likely to grow to about 57.3 M, while Total Revenue is likely to drop slightly above 140.1 M.

Total Revenue Gross Profit Other Operating Expenses Ebit Research Development Net Income

Total Revenue

Total revenue comprises all receipts Lifecore Biomedical generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Lifecore Biomedical minus its cost of goods sold. It is profit before Lifecore Biomedical operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Lifecore Biomedical. It is also known as Lifecore Biomedical overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Lifecore Biomedical financial statement analysis. It represents the amount of money remaining after all of Lifecore Biomedical operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most accounts from Lifecore Biomedical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Lifecore Biomedical current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.At this time, Lifecore Biomedical's Net Income is relatively stable compared to the past year. As of 03/01/2025, Selling General Administrative is likely to grow to about 57.3 M, while Total Revenue is likely to drop slightly above 140.1 M.

	2023	2024	2025 (projected)
Total Revenue	128.3M	147.5M	140.1M
Interest Expense	18.1M	20.8M	21.8M

Total Revenue Interest Expense

Lifecore Biomedical income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Selling And Marketing Expenses	Tax Provision	Net Interest Income	Interest Income	Discontinued Operations	Net Income From Continuing Ops	Reconciled Depreciation
Depreciation And Amortization		0.14	0.05	0.3	0.02	0.03	-0.36	0.26	-0.18	0.02	0.24	0.08	0.07	-0.14	0.08	-0.03	0.26	0.31	-0.15	-0.06	-0.24	0.05	-0.12
Interest Expense	0.14		-0.53	-0.19	-0.43	-0.19	-0.14	0.02	-0.05	-0.56	0.19	-0.46	-0.34	-0.43	-0.36	0.3	-0.67	-0.37	-0.98	-0.96	-0.92	-0.36	-0.37
Total Revenue	0.05	-0.53		0.89	0.98	-0.02	0.1	0.55	0.06	1.0	0.66	0.07	-0.04	0.15	-0.03	0.46	0.59	-0.19	0.56	0.44	0.56	0.02	0.56
Gross Profit	0.3	-0.19	0.89		0.91	0.01	0.05	0.73	0.09	0.87	0.84	-0.02	-0.08	0.06	-0.12	0.6	0.44	-0.22	0.23	0.13	0.24	-0.07	0.39
Other Operating Expenses	0.02	-0.43	0.98	0.91		-0.05	0.13	0.55	0.11	0.97	0.68	0.07	-0.05	0.16	-0.06	0.56	0.55	-0.22	0.49	0.37	0.5	0.05	0.54
Operating Income	0.03	-0.19	-0.02	0.01	-0.05		0.46	0.07	0.48	-0.02	-0.3	0.72	0.66	0.57	0.74	-0.47	-0.01	0.44	0.17	0.21	0.2	0.35	-0.33
Ebit	-0.36	-0.14	0.1	0.05	0.13	0.46		0.05	0.98	0.1	-0.16	0.66	0.66	0.86	0.45	-0.15	0.04	0.43	0.2	0.11	0.44	0.61	-0.49
Research Development	0.26	0.02	0.55	0.73	0.55	0.07	0.05		0.09	0.52	0.78	0.0	0.05	0.11	-0.27	0.54	0.04	-0.27	0.04	-0.05	0.06	-0.04	0.12
Ebitda	-0.18	-0.05	0.06	0.09	0.11	0.48	0.98	0.09		0.05	-0.13	0.7	0.7	0.87	0.47	-0.13	0.05	0.51	0.12	0.05	0.35	0.66	-0.58
Cost Of Revenue	0.02	-0.56	1.0	0.87	0.97	-0.02	0.1	0.52	0.05		0.63	0.08	-0.03	0.16	-0.02	0.44	0.6	-0.19	0.59	0.47	0.59	0.04	0.57
Total Operating Expenses	0.24	0.19	0.66	0.84	0.68	-0.3	-0.16	0.78	-0.13	0.63		-0.38	-0.36	-0.24	-0.48	0.84	0.16	-0.54	-0.13	-0.24	-0.12	-0.3	0.29
Income Before Tax	0.08	-0.46	0.07	-0.02	0.07	0.72	0.66	0.0	0.7	0.08	-0.38		0.85	0.91	0.8	-0.44	0.3	0.73	0.52	0.55	0.58	0.87	-0.43
Total Other Income Expense Net	0.07	-0.34	-0.04	-0.08	-0.05	0.66	0.66	0.05	0.7	-0.03	-0.36	0.85		0.86	0.68	-0.39	0.17	0.78	0.38	0.4	0.52	0.64	-0.46
Net Income	-0.14	-0.43	0.15	0.06	0.16	0.57	0.86	0.11	0.87	0.16	-0.24	0.91	0.86		0.59	-0.25	0.29	0.65	0.5	0.47	0.66	0.85	-0.46
Income Tax Expense	0.08	-0.36	-0.03	-0.12	-0.06	0.74	0.45	-0.27	0.47	-0.02	-0.48	0.8	0.68	0.59		-0.57	0.14	0.63	0.37	0.42	0.39	0.55	-0.29
Selling General Administrative	-0.03	0.3	0.46	0.6	0.56	-0.47	-0.15	0.54	-0.13	0.44	0.84	-0.44	-0.39	-0.25	-0.57		0.05	-0.63	-0.19	-0.32	-0.16	-0.22	0.32
Selling And Marketing Expenses	0.26	-0.67	0.59	0.44	0.55	-0.01	0.04	0.04	0.05	0.6	0.16	0.3	0.17	0.29	0.14	0.05		0.42	0.68	0.69	0.64	0.33	0.16
Tax Provision	0.31	-0.37	-0.19	-0.22	-0.22	0.44	0.43	-0.27	0.51	-0.19	-0.54	0.73	0.78	0.65	0.63	-0.63	0.42		0.37	0.48	0.43	0.61	-0.54
Net Interest Income	-0.15	-0.98	0.56	0.23	0.49	0.17	0.2	0.04	0.12	0.59	-0.13	0.52	0.38	0.5	0.37	-0.19	0.68	0.37		0.97	0.96	0.47	0.33
Interest Income	-0.06	-0.96	0.44	0.13	0.37	0.21	0.11	-0.05	0.05	0.47	-0.24	0.55	0.4	0.47	0.42	-0.32	0.69	0.48	0.97		0.89	0.46	0.24
Discontinued Operations	-0.24	-0.92	0.56	0.24	0.5	0.2	0.44	0.06	0.35	0.59	-0.12	0.58	0.52	0.66	0.39	-0.16	0.64	0.43	0.96	0.89		0.53	0.21
Net Income From Continuing Ops	0.05	-0.36	0.02	-0.07	0.05	0.35	0.61	-0.04	0.66	0.04	-0.3	0.87	0.64	0.85	0.55	-0.22	0.33	0.61	0.47	0.46	0.53		-0.46
Reconciled Depreciation	-0.12	-0.37	0.56	0.39	0.54	-0.33	-0.49	0.12	-0.58	0.57	0.29	-0.43	-0.46	-0.46	-0.29	0.32	0.16	-0.54	0.33	0.24	0.21	-0.46

Click cells to compare fundamentals

Lifecore Biomedical Account Relationship Matchups

Lifecore Biomedical income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	8.6M	17.9M	7.1M	8.9M	10.2M	6.4M
Interest Expense	15.3M	17.4M	17.3M	18.1M	20.8M	21.8M
Total Revenue	590.4M	544.2M	185.8M	128.3M	147.5M	140.1M
Gross Profit	81.5M	50.4M	50.6M	41.9M	48.1M	50.2M
Other Operating Expenses	538.3M	189.4M	185.7M	135.4M	155.8M	308.9M
Operating Income	(6.9M)	(3.6M)	3.5M	9.3M	10.7M	5.7M
Ebit	4.4M	(85.9M)	(5.1M)	26.7M	24.1M	25.3M
Research Development	11.1M	10.2M	7.8M	8.6M	9.9M	7.4M
Ebitda	13.0M	(68.0M)	2.0M	35.6M	40.9M	43.0M
Cost Of Revenue	462.7M	135.4M	135.2M	86.4M	99.4M	94.4M
Total Operating Expenses	75.6M	54.0M	50.5M	49.0M	56.4M	42.6M
Income Before Tax	(40.5M)	(52.1M)	(51.9M)	9.5M	8.6M	9.0M
Total Other Income Expense Net	(21.0M)	(48.5M)	(8.9M)	183K	164.7K	172.9K
Net Income	(32.7M)	(97.4M)	(46.1M)	12.0M	10.8M	11.4M
Income Tax Expense	(13.1M)	(7.8M)	(5.8M)	183K	164.7K	156.5K
Selling General Administrative	65.3M	46.1M	42.4M	43.0M	49.5M	57.3M
Tax Provision	(7.8M)	(5.8M)	301K	183K	210.5K	221.0K
Net Interest Income	(15.3M)	(17.3M)	(18.1M)	(18.1M)	(16.3M)	(17.1M)
Interest Income	103K	48K	81K	68K	61.2K	71.2K
Discontinued Operations	(16.3M)	(23.1M)	(51.2M)	(33.2M)	(29.9M)	(31.4M)
Net Income From Continuing Ops	(32.7M)	(46.3M)	(69.0M)	9.3M	8.4M	8.8M
Reconciled Depreciation	19.9M	17.9M	13.5M	8.9M	8.0M	12.6M
Net Income Applicable To Common Shares	(38.2M)	(32.7M)	(97.4M)	(102.2M)	(92.0M)	(87.4M)

Additional Tools for Lifecore Stock Analysis

When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lifecore Historical Income Statement

About Lifecore Income Statement Analysis

Lifecore Biomedical Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Net Income

Lifecore Biomedical income statement Correlations

Lifecore Biomedical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lifecore Biomedical income statement Accounts

Additional Tools for Lifecore Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cost Of Revenue	+ 1.0	Total Revenue
Other Operating Expenses	+ 0.98	Total Revenue
Ebitda	+ 0.98	Ebit
Cost Of Revenue	+ 0.97	Other Operating Expenses
Interest Income	+ 0.97	Net Interest Income
Discontinued Operations	+ 0.96	Net Interest Income

Net Interest Income	- 0.98	Interest Expense
Interest Income	- 0.96	Interest Expense
Discontinued Operations	- 0.92	Interest Expense
Selling And Marketing Expenses	- 0.67	Interest Expense
Tax Provision	- 0.63	Selling General Administrative
Reconciled Depreciation	- 0.58	Ebitda